Oragenics Inc
OGEN1.260USD
+0.010+0.79%
Horário de mercado （ET）Cotações atrasadas em 15 min
27.06MValor de mercado
PerdaP/L TTM
Mais detalhes de Oragenics Inc Empresa
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.
Informações da empresa
Código da empresaOGEN
Nome da EmpresaOragenics Inc
Data de listagemJul 09, 2003
CEOMs. Janet Huffman
Número de funcionários3
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 09
Endereço1990 Main Street
CidadeSARASOTA
Bolsa de valoresNYSE American Consolidated
PaísUnited States of America
Código postal34236
Telefone18132867900
Sitehttps://www.oragenics.com/
Código da empresaOGEN
Data de listagemJul 09, 2003
CEOMs. Janet Huffman
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Frederick W. Telling, Ph.D.
Dr. Frederick W. Telling, Ph.D.
Independent Director
Independent Director
1.16K
--
Mr. Robert C. Koski
Mr. Robert C. Koski
Independent Director
Independent Director
931.00
--
Mr. Charles L. Pope
Mr. Charles L. Pope
Executive Chairman of the Board
Executive Chairman of the Board
849.00
--
Ms. Janet Huffman
Ms. Janet Huffman
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
500.00
--
Mr. John P. Gandolfo
Mr. John P. Gandolfo
Independent Director
Independent Director
--
--
Dr. James Kelly, M.D.
Dr. James Kelly, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Alan William Dunton, M.D.
Dr. Alan William Dunton, M.D.
Independent Director
Independent Director
--
--
Mr. Tirth T. Patel
Mr. Tirth T. Patel
Vice President
Vice President
--
--
Dr. William (Frank) Peacock, M.D.
Dr. William (Frank) Peacock, M.D.
Chief Clinical Officer
Chief Clinical Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Frederick W. Telling, Ph.D.
Dr. Frederick W. Telling, Ph.D.
Independent Director
Independent Director
1.16K
--
Mr. Robert C. Koski
Mr. Robert C. Koski
Independent Director
Independent Director
931.00
--
Mr. Charles L. Pope
Mr. Charles L. Pope
Executive Chairman of the Board
Executive Chairman of the Board
849.00
--
Ms. Janet Huffman
Ms. Janet Huffman
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
500.00
--
Mr. John P. Gandolfo
Mr. John P. Gandolfo
Independent Director
Independent Director
--
--
Dr. James Kelly, M.D.
Dr. James Kelly, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 29 de jul
Atualizado em: ter, 29 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Five Narrow Lane LP
9.99%
Cassidy (Bruce A Sr)
1.44%
Geode Capital Management, L.L.C.
0.34%
Two Sigma Investments, LP
0.18%
Telling (Frederick W)
0.14%
Other
87.91%
Investidores
Investidores
Proporção
Five Narrow Lane LP
9.99%
Cassidy (Bruce A Sr)
1.44%
Geode Capital Management, L.L.C.
0.34%
Two Sigma Investments, LP
0.18%
Telling (Frederick W)
0.14%
Other
87.91%
Tipos de investidores
Investidores
Proporção
Corporation
10.05%
Individual Investor
2.06%
Investment Advisor/Hedge Fund
0.35%
Investment Advisor
0.30%
Hedge Fund
0.21%
Venture Capital
0.10%
Other
86.93%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
51
25.35K
3.08%
-29.87K
2025Q1
54
104.53K
39.81%
+67.24K
2024Q4
61
3.11M
25.46%
+2.05M
2024Q3
59
1.22M
18.08%
+226.05K
2024Q2
58
1.45M
24.58%
+674.78K
2024Q1
57
1.51M
26.60%
+861.00K
2023Q4
59
1.13M
28.10%
+795.74K
2023Q3
58
266.28K
10.68%
+19.84K
2023Q2
53
93.56K
4.68%
-159.82K
2023Q1
59
99.61K
5.08%
-139.03K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Cassidy (Bruce A Sr)
11.82K
1.44%
+3.00
+0.03%
Mar 21, 2025
Geode Capital Management, L.L.C.
2.83K
0.34%
+1.54K
+120.42%
Mar 31, 2025
Two Sigma Investments, LP
1.45K
0.18%
+224.00
+18.35%
Mar 31, 2025
Telling (Frederick W)
1.16K
0.14%
--
--
Mar 21, 2025
Koski (Robert C)
931.00
0.11%
--
--
Mar 21, 2025
Dunton (Alan W)
854.00
0.1%
--
--
Mar 21, 2025
Pope (Charles L)
849.00
0.1%
--
--
Mar 21, 2025
Murphy (Kimberly M)
833.00
0.1%
--
--
Mar 21, 2025
XTX Markets LLC
828.00
0.1%
-470.00
-36.21%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
Data
Tipo
Proporção
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
